Table 1. Demographics and baseline characteristics.
| All Patients (N = 54) | |
|---|---|
| Sex, n (%) | |
| Male | 36 (66.7) |
| Female | 18 (33.3) |
| Race, n (%) | |
| White/Caucasian | 39 (72.2) |
| Hispanic/Latino | 7 (13.0) |
| Black/African American | 5 (9.3) |
| Asian | 3 (5.6) |
| Age, median (range), y | 60.5 (39–80) |
| ECOG performance status at baseline, n (%) | |
| 0 | 28 (52) |
| 1 | 26 (48) |
| Disease stage, n (%) | |
| II | 1 (2) |
| III | 4 (7) |
| IV | 48 (89) |
| Unknown | 1 (2) |
| Primary tumor type, n (%) | |
| Prostate | 10 (18.5) |
| Colon | 6 (11.1) |
| Esophageal | 6 (11.1) |
| Non-small cell lung | 6 (11.1) |
| Kidney | 5 (9.3) |
| Head and neck squamous cell carcinoma | 3 (5.6) |
| Bladder | 2 (3.7) |
| Carcinoma of unknown origin | 2 (3.7) |
| Malignant melanoma | 2 (3.7) |
| Ovarian | 2 (3.7) |
| Stomach | 1 (1.9) |
| Cervix | 1 (1.9) |
| Oral | 1 (1.9) |
| Pancreas | 1 (1.9) |
| Soft tissue sarcoma | 1 (1.9) |
| Uterine | 1 (1.9) |
| Othera | 4 (7.4) |
| Prior radiotherapy, n (%) | 32 (59.3) |
| Number of prior chemotherapy regimens, n (%) | |
| 1 | 4 (7) |
| 2 | 15 (28) |
| ≥3 | 35 (65) |
a
Includes adenoid cystic carcinoma, appendiceal adenocarcinoma, metastatic insular thyroid cancer, and poorly differentiated adenocarcinoma of the gallbladder. ECOG, Eastern Cooperative Oncology Group.